Neurana Pharmaceuticals, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: San Diego CA United States (2013)

Organization Overview

First Clinical Trial
2017
NCT03353922
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Neurana Pharmaceuticals | Neurana Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

cyclobenzaprine (flexeril) (3 trials)

Drugs in Phase 2 Trials (1)

tolperisone (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 3)

Back Pain (Phase 2)

Hyperkinesis (Phase 3)

Low Back Pain (Phase 2)

Muscle Cramp (Phase 3)

Sleepiness (Phase 1)

Spasm (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 2